Canopus Networks Unveils SEER: Revolutionary Real-Time Network Observability Platform for Enterprises.
- Canopus SEER is a real-time network observability platform using Agentic-AI to address monitoring data challenges.
- It offers high-quality, real-time data to eliminate visibility issues, enhancing proactive network management for teams.
- SEER's advanced capabilities enable organizations to process vast data efficiently, improving decision-making and operational efficiency.
Canopus Networks Launches SEER: A Game-Changer in Network Observability
Canopus Networks introduces Canopus SEER, a pioneering real-time network observability platform driven by Agentic-AI, tailored for enterprises and carriers grappling with the challenges of extensive monitoring data. Developed over a span of 12 years, SEER is founded on eight patents and over 30 academic publications, addressing the pervasive issue of reactive observability. This problem is characterized by reliance on fragmented, low-fidelity data that generates excessive alerts and requires time-consuming manual investigations. Bhaskar Dutta, Chief Product Officer at Canopus Networks, highlights that existing network telemetry systems are inefficient for agentic workflows, leading to delays and blind spots. In response, Canopus SEER is engineered to eliminate this "visibility paradox," offering high-quality, real-time data that empowers network teams with the support of AI-driven agents.
The platform incorporates cutting-edge cloud-native eBPF sensors capable of extracting real-time telemetry data from all network traffic, including encrypted communications, at an astonishing speed of 100 milliseconds and a scale of up to 400 Gbps on a single node. This functionality provides unprecedented visibility into both individual users and applications. The core innovations of Canopus SEER enable operations teams to effectively Sense, Examine, Evaluate, and Respond to network activities. Its patented algorithms contextualize billions of real-time flows, producing detailed application and behavioral fingerprints. This advancement is crucial as it allows for a nuanced understanding of network dynamics, ensuring that teams can take proactive measures rather than reactive ones.
Professor Vijay Sivaraman, founder and CEO of Canopus Networks, underscores the importance of high-quality data ingestion for the efficacy of AI in observability. He asserts that a radically different approach is essential to achieve observability at scale, which SEER aims to provide. By focusing on delivering faster, cheaper, and more efficient decision-making capabilities, Canopus SEER has the potential to revolutionize network operations, enabling organizations to manage their networks more effectively and respond to incidents with greater agility.
In addition to its advanced features, Canopus SEER represents a significant shift towards proactive network management, moving away from traditional methods that often leave teams overwhelmed by alerts. The platform's ability to process vast amounts of data in real-time positions it as a critical tool for organizations looking to enhance their operational efficiency.
As the demand for robust network observability solutions continues to escalate, Canopus SEER stands out as a groundbreaking development that promises to reshape how enterprises and carriers approach network management, paving the way for smarter and more responsive network operations.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

